5‐HT3 antiemetic therapy for patients with breast cancer

[1]  E. Perez,et al.  Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[3]  E. Perez,et al.  Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. , 1998, The cancer journal from Scientific American.

[4]  L. Frakes,et al.  An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant , 1997, Bone Marrow Transplantation.

[5]  J. Hainsworth,et al.  Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Navari,et al.  Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. , 1997, Cancer investigation.

[7]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Perez,et al.  Paclitaxel and carboplatin for advanced breast cancer. , 1996, Seminars in oncology.

[9]  D. Ettinger,et al.  A double‐blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy , 1996, Cancer.

[10]  T. Conroy,et al.  A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. , 1996, European journal of cancer.

[11]  F. Roila.  Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  U. Tirelli,et al.  Ondansetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting , 1995 .

[13]  Héron Jf.  Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: a double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. , 1995 .

[14]  W. Plunkett,et al.  Induction of apoptosis by gemcitabine. , 1995, Seminars in oncology.

[15]  P. Hesketh.  Prophylaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. , 1995, Seminars in oncology.

[16]  M. Spielmann,et al.  Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. , 1995, Clinical therapeutics.

[17]  K. Jenns,et al.  Importance of nausea , 1994, Cancer nursing.

[18]  V. Gebbia,et al.  Ondasetron versus granisetron in the prevention of chemotherapy‐induced nausea and vomiting. Results of a prospective randomized trial , 1994, Cancer.

[19]  M. Latteri,et al.  Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. , 1994, Cancer.

[20]  A. Ciociola,et al.  Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy , 1993, Annals of Internal Medicine.

[21]  D. Christmann,et al.  Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. , 1991, European journal of cancer.

[22]  C. Seynaeve,et al.  Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. , 1990, Annals of internal medicine.

[23]  M. O’Connell,et al.  Management of Chemotherapy‐Induced Nausea and Vomiting , 1990, Pharmacotherapy.

[24]  G. Morrow.  Chemotherapy‐related nausea and vomiting: Etiology and management , 1989, CA: a cancer journal for clinicians.

[25]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.